Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Study on Internet Medical Models for the Management of Patients With Hypertension in China

30. januar 2019 opdateret af: China Cardiovascular Association

A Comparative Study on Internet Medical Models and Conventional Medical Models for the Management of Patients With Hypertension in China

The study is a multi-center, randomized, open, and parallel study. Approximately 958 subjects will be enrolled in 16 sites. The random number table will be adopted to conduct cluster randomization per township hospital/community health service center. Patients will be randomized 1:1 to receive blood pressure management in Internet medical model or Conventional medical model. After follow-ups of 3 months and 6 months, the blood pressure in each group will be observed and compared.

Studieoversigt

Status

Ukendt

Betingelser

Detaljeret beskrivelse

Protocol Title:A Comparative Study on Internet Medical Models and Conventional Medical Models for the Management of Patients with Hypertension in China Study Indication:Hypertension Number of Site:16sites Study Duration (from the initiation of the first site to the end of the follow-up for the last subject): 12 months Duration of Treatment and Management: 6 months Planned Number of Subjects:958 subjects, 479 in each group(blood pressure management in Internet medical model, Conventional medical model) Internet Medical Model:Using Internet blood pressure management model: home blood pressure self-monitoring + Internet diagnosis + Maintained or adjusted anti-hypertension drug(s) treatment.

Conventional Medical Model:Using Conventional blood pressure management model: home blood pressure monitoring + face-to-face diagnosis in clinic + Maintained or adjusted anti-hypertension drug(s) treatment.

Inclusion Criteria:

  1. Male or female, 45 to 75 years old (including 45and 75 years);
  2. Two measurements of resting systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90mmHg on different days during screening;
  3. Female subjects of child-bearing potential who are willing to adopt one of the following methods for contraception during the study:

    • Oral contraceptive, either combined or progestogen alone.
    • Injectable progestogen.
    • Implants of levonorgestrel.
    • Oestrogenic vaginal ring.
    • Percutaneous contraceptive patches.
    • Intrauterine device or intrauterine system showing that the expected failure rate is less than 1% per year as stated in the product label.
    • Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository).
  4. Subjects who can understand and perform home blood pressure monitoring as required by the study;
  5. Subjects who voluntarily participate in the study and sign informed consent form.

Exclusion Criteria:

  1. Two measurements of resting systolic blood pressure ≥ 180mmHg and/or diastolic blood pressure ≥ 110mmHg on different days during screening;
  2. Subjects with the history of cerebral stroke within 6 months prior to screening;
  3. Subjects with the history of myocardial infarction within 6 months prior to screening;
  4. Subjects with the history of heart failure;
  5. Subjects with the history of atrial fibrillation;
  6. Subjects with the history of coronary artery revascularization;
  7. Subjects with other serious diseases, such as tumor;
  8. Subjects diagnosed as the secondary hypertension;
  9. Subjects with congenital or acquired organic heart disease;
  10. Pregnant or lactant subjects;
  11. Subjects with severe mental disease;
  12. Subjects with abnormal liver and renal function: ALT or AST>2 X upper limit value; Or creatinine > 2X upper limit value
  13. Subjects who were previously diagnosed with diabetes that is currently poorly controlled: FBG>10mmol/L;
  14. Subjects who are unable to conduct blood pressure self-test;
  15. The subject has any other known condition at screening that would compromise subject safety, might affect life expectancy, or making it difficult to successfully manage and follow the subject according to the protocol.

Efficacy Evaluations:

Primary Efficacy Endpoints:

  • Blood pressure control rate of subjects in the two groups at Month 6 Secondary Efficacy Endpoints:
  • Blood pressure control rate of subjects in the two groups at Month 3
  • Blood pressure value of subjects in the two groups at Month 3 and Month 6
  • Change of blood pressure of subjects in the two groups at Month 3 and Month 6
  • Variability of blood pressure of subjects in the two groups at Month 3 and Month 6
  • Treatment compliance of subjects in the two groups at Month 3 and Month 6
  • Medical expense of subjects in the two groups at Month 3 and Month 6
  • Treatment satisfaction of subjects in the two groups at Month 3 and Month 6

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

958

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

45 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Male or female, 45 to 75 years old (including 45 and 75 years);
  2. Two measurements of resting systolic blood pressure ≥140mmHg and/or diastolic blood pressure ≥90mmHg on different days during screening;
  3. Female subjects of child-bearing potential who are willing to adopt one of the following methods for contraception during the study:

    Oral contraceptive, either combined or progestogen alone. Injectable progestogen. Implants of levonorgestrel. Oestrogenic vaginal ring. Percutaneous contraceptive patches. Intrauterine device or intrauterine system showing that the expected failure rate is less than 1% per year as stated in the product label.

    Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository).

  4. Subjects who can understand and perform home blood pressure monitoring as required by the study;
  5. Subjects who voluntarily participate in the study and sign informed consent form.

Exclusion Criteria:

  1. Two measurements of resting systolic blood pressure ≥180mmHg and/or diastolic blood pressure ≥110mmHg on different days during screening;
  2. Subjects with the history of cerebral stroke within 6 months prior to screening;
  3. Subjects with the history of myocardial infarction within 6 months prior to screening;
  4. Subjects with the history of heart failure;
  5. Subjects with the history of atrial fibrillation;
  6. Subjects with the history of coronary artery revascularization;
  7. Subjects with other serious diseases, such as tumor;
  8. Subjects diagnosed as the secondary hypertension;
  9. Subjects with congenital or acquired organic heart disease;
  10. Pregnant or lactant subjects;
  11. Subjects with severe mental disease;
  12. Subjects with abnormal liver and renal function: ALT or AST>2 X upper limit value; Or creatinine >2 X upper limit value;
  13. Subjects who were previously diagnosed with diabetes that is currently poorly controlled: FBG>10mmol/L;
  14. Subjects who are unable to conduct blood pressure self-test;
  15. The subject has any other known condition at screening that would compromise subject safety, might affect life expectancy, or making it difficult to successfully manage and follow the subject according to the protocol.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Andet
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Andet: Internet Medical Model
Using Internet blood pressure management model: home blood pressure self-monitoring + Internet diagnosis + Maintained or adjusted anti-hypertension drug(s) treatment.
Subjects in the Internet group should upload blood pressure monitoring data at least once per day. It is highly recommended to upload two pressure monitoring results to capture more blood pressure information. The warning value of blood pressure set in the cloud database is systolic blood pressure ≥ 180mmHg or ≤ 100mmHg and diastolic blood pressure ≥ 110mmHg or ≤ 60mmHg. After enrollment, subjects and physicians communicate via telephone or Internet every two weeks until blood pressure is well controlled judged by physician. Then the frequency of communication will be changed to once a month. Once there are lacks of blood pressure data in 3 days of each week, or. blood pressure values of the subject exceed the warning value in 2 days of consecutive 3 days, the physician will take the initiative to contact the patient for disease inquiry.
Ingen indgriben: Conventional Medical Model
Using Conventional blood pressure management model: home blood pressure monitoring + face-to-face diagnosis in clinic + Maintained or adjusted anti-hypertension drug(s) treatment.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Primary endpoint: blood pressure control rate of subjects in the two groups at Month 6
Tidsramme: 6 months
Definition of blood pressure control rate is that the percent of subjects with systolic blood pressure <140 mm Hg and diastolic blood pressure < 90 mm Hg
6 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Forventet)

1. marts 2019

Primær færdiggørelse (Forventet)

1. september 2019

Studieafslutning (Forventet)

1. december 2019

Datoer for studieregistrering

Først indsendt

4. maj 2018

Først indsendt, der opfyldte QC-kriterier

16. maj 2018

Først opslået (Faktiske)

17. maj 2018

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

31. januar 2019

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

30. januar 2019

Sidst verificeret

1. januar 2019

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

Ingen

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner